Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 4/20 | 0.42 |
| ▸ | LCK | P06239 | 6/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31311202 | 0.91 | BRAF (0.43) | LCKBRAFTRPV4ALDH1A1PKM | |
| SCHEMBL31311210 | 0.85 | LCK (0.45) | MPLLCKBRAFABL1ALDH1A1 | |
| SCHEMBL31311339 | 0.84 | PLTP (0.44) | MPLLCKBRAFABL1ALDH1A1 | |
| SCHEMBL31311342 | 0.83 | MPL (0.40) | MPLLCKBRAFABL1ALDH1A1 | |
| SCHEMBL31311187 | 0.82 | LCK (0.48) | MPLLCKABL1ALDH1A1PKM | |
| SCHEMBL31311335 | 0.81 | ALDH1A1 (0.48) | LCKABL1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL31311367 | 0.78 | PLTP (0.48) | LCKABL1SMN1; SMN2RORCMAPT | |
| SCHEMBL31311370 | 0.75 | ABL1 (0.71) | ABL1PKMMAPT | |
| SCHEMBL31311213 | 0.75 | LCK (0.45) | LCKBRAFALDH1A1PKM | |
| SCHEMBL31311393 | 0.74 | PLTP (0.46) | MPLLCKBRAFALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731206-A2 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | Veralox Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| WO-2024264032-A2 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | VERALOX THERAPEUTICS INC. (US) | 2024-12-26 | — | — | WO | disclosed |